Multiple lines of evidence link high blood pressure and insulin resistance. However the influence of insulin resistance on hypertension in type 2 diabetics remains to be assessed to compare insulin resistance in hypertensive and normotensive patients with type 2 diabetes The study group concerned 41 patients recruited in an outpatient clinic. 23 patients with BPϾ130/85 mmHg were identified as mild hypertensive (20 from 23 under treatment). Insulin sensitivity was assessed with the use of the euglycemic insulin-clamp technique and biologic parameters such as lipids, PAI-1, insulin and proinsulin. An ambulatory blood pressure monitoring was performed in all patients.
. We characterized the renal endothelin system in diet-induced obesity and determined the effects of chronic treatment with the ET A antagonist darusentan. C57BL/6J mice were fed a standard diet (control) or a high-fat diet (Harlan TD88137) with or without darusentan (50 mg/kg/d, 30 wk). Total RNA was extracted from whole kidneys and mRNA expression of preproendothelin-1 (ppET-1), ET A receptors, and ␤-actin were determined by RT-PCR using mousespecific primers. PCR-products were normalized vs. ␤-actin or 18S rRNA. Renal ET-1 protein was measured by RIA/HPLC. High fat diet increased body weight by 257% compared to 54% (control diet). Darusentan had no effect on body weight in obese mice (263%) and treatments had no effect on systolic blood pressure. Obesity was associated with upregulation of renal ET A receptors (144Ϯ5% vs 100Ϯ7%, pϽ0.05 vs. control) and to a lesser extent, preproendothelin-1 (113Ϯ5% vs.100Ϯ2%, pϽ0.05 vs. control). In obese mice chronic darusentan treatment in part prevented the ET A receptor upregulation (126% vs. 144Ϯ5%, pϽ0.05) but had no significant effect on ppET-1 mRNA expression (101Ϯ9 vs. 100Ϯ2%, n.s.). Renal ET-1 protein increased in obese animals (from 190Ϯ18 to 267Ϯ19 pg/g tissue, pϽ0.05 vs. control). This increase was not affected by concomitant darusentan treatment (n.s.).
These data for the first time demonstrate that obesity in normotensive rats is associated with upregulation of renal ET A receptor expression suggesting that body weight per se affects ET receptor expression in the kidney. Our data further indicate that in this model ET A receptors control expression of the ET A receptor but not the ppET-1 gene, suggesting autocrine regulation in vivo. These mechanisms might contribute to the pathogenesis of obesity-associated diseases affecting the kidney and/or blood pressure.
Key Words: obesity, hypertension, kidney All 214 subjects with elevated blood pressure (BP)(Ն140/Ն90 mmHg) were selected from the total pool of overweight or obese individuals who completed one year of treatment consisting of diet ϩ placebo (P) or diet ϩ orlistat (O). Compared to subjects with normal fasting insulin levels (Ͻ90 pm/L), hypertensive subjects with high fasting insulin levels (Ն90 pm/L) had significantly higher (pϽ0.05) initial values for body weight, fasting glucose, LDL-cholesterol (LDL-C), LDL/HDL-C, triglycerides and systolic BP plus lower levels of HDL-C.
P-591 EFFECT OF ORLISTAT IN PATIENTS WITH HYPERTENSION AND EITHER HIGH OR NORMAL FASTING INSULIN LEVELS
After 1 year, no significant differences were observed between O and P in normal insulin subjects for changes in blood pressure, glucose, insulin or lipids despite greater weight loss with O vs P (-10.3Ϯ1.0% vs -6.4 Ϯ 0.9%, pϭ0.0028). In high insulin subjects, the following changes were significantly greater for O than P: body weight (-9.3 Ϯ 0.7% vs -5.2 Ϯ 0.6%, pϭ0.0001), systolic BP (-17.6 Ϯ 1.7 vs -12.6 Ϯ 1.8 mmHg, pϭ0.035), diastolic BP (-10.6 Ϯ 1.1 vs -8.5 Ϯ 1.2 mmHg, pϭ0.022), insulin (-39 Ϯ 5.8 vs -25 Ϯ 7.5 pm/L, pϭ0.013), LDL-C (-0.49 Ϯ 0.09 vs -0.18 Ϯ 0.08 mm/L, pϭ0.035), or LDL/HDL-C (-0.44 Ϯ 0.09 vs -0.09 Ϯ 0.09, pϭ0.044).
In conclusion, CV risk factors are more likely to be abnormal in high insulin hypertension, and orlistat was more effective than placebo in improving these risk factors.
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P-592 CARDIOVASCULAR EVENTS AND ABNORMALITIES OF GLUCOSE METABOLISM IN PATIENTS WITH HYPERTENSIVE NEPHROSCLEROSIS AND REDUCED CREATININE CLEARANCE
Laura Zingaro, Cristiana Catena, Daniele Casaccio, Sergio De Marchi, Leonardo A. Sechi. 1 Internal Medicine, DPMSC, University of Udine, Udine, Italy Abnormalities of glucose metabolism and hyperinsulinemia have been demonstrated in patients with end-stage renal disease and may contribute to the development of atherosclerotic complications in these patients. This study was performed in hypertensive patients with mild to moderate impairment of renal function to investigate at what stage of renal failure abnormalities of glucose metabolism develop and whether these abnormalities are associated with increased prevalence of cardiovascular events. In 321 untreated essential hypertensive patients recruited at a hypertension clinic and 92 matched normotensive controls we assessed the renal function by measurement of 24-hour creatinine clearance, urinary protein excretion, 227A AJH-April 2001-VOL. 14, NO. 4, PART 2 POSTERS: Obesity, Insulin Resistance, Diabetes
